Ipca Laboratories Sustainability Profile
Ipca Laboratories Limited, headquartered in Mumbai, India, is a prominent player in the pharmaceutical industry, specialising in the manufacture and export of active pharmaceutical ingredients (APIs) and finished dosage forms. Founded in 1949, the company has achieved significant milestones, including a robust presence in over 100 countries and a diverse product portfolio that encompasses a wide range of therapeutic areas such as cardiovascular, anti-infective, and pain management. With a commitment to quality and innovation, Ipca Laboratories stands out for its extensive range of generic formulations and APIs, which are produced in state-of-the-art facilities adhering to international standards. The company has garnered a strong market position, recognised for its consistent growth and contributions to healthcare, making it a trusted name in the global pharmaceutical landscape.
DitchCarbon Score
How does Ipca Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ipca Laboratories's score of 37 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ipca Laboratories's reported carbon emissions
In 2025, Ipca Laboratories reported total carbon emissions of approximately 169,992,000 kg CO2e for Scope 1, 124,512,000 kg CO2e for Scope 2, and 287,887,000 kg CO2e for Scope 3 emissions. This reflects a comprehensive approach to emissions reporting, covering all three scopes. In 2024, the company recorded emissions of about 174,538,000 kg CO2e for Scope 1, 137,345,000 kg CO2e for Scope 2, and 306,660,000 kg CO2e for Scope 3. Ipca Laboratories has set ambitious targets to reduce its carbon emissions by 20% by 2030 for both Scope 1 and Scope 2 emissions, starting from 2022. This commitment aligns with their broader sustainability goals and reflects a proactive stance in addressing climate change. The company is also committed to achieving net-zero emissions, although specific timelines for this target have not been disclosed. The emissions data is not cascaded from any parent organization, indicating that Ipca Laboratories independently manages its climate commitments and reporting. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector, which is increasingly scrutinised for its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Scope 1 | 151,862,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 174,694,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 |
How Carbon Intensive is Ipca Laboratories's Industry?
How Carbon Intensive is Ipca Laboratories's Location?
Ipca Laboratories's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ipca Laboratories has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Ipca Laboratories's sustainability data and climate commitments